ASCO 2014: Clovis, AstraZeneca face off with EGFR, PARP inhibitors
This article was originally published in Scrip
Clovis Oncology and AstraZeneca are showing data for two sets of competing drugs at the 50th Annual American Society of Clinical Oncology (ASCO) Meeting in Chicago, kicking off the first full day of abstract presentations with updated clinical trial results for Clovis's CO-1686 and rucaparib and AstraZeneca's AZD9291 and olaparib.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.